You are here

Article Text

Article menu

Download PDFPDF

Ovarian cancer
2022-RA-437-ESGO Meta-analyses reveal serum or plasma interleukin-6 as a biomarker for malignant ovarian neoplasia
Free
  1. Andrei Pasca1,2,
  2. Eva Fischer-Fodor3,
  3. Nicoleta Monica Jiboc4,
  4. Paul Milan Kubelac5,
  5. Bhaskar Saha6,
  6. Eduard Alexandru Bonci1,2,
  7. Vlad Alexandru Gata1,2,
  8. Catalin Vlad1,2 and
  9. Patriciu Andrei Achimas-Cadariu1,2
  1. 1Surgical Oncology and Gynaecological Oncology, ‘Iuliu Hatieganu’ University of Medicine and Pharmacy, Cluj-Napoca, Romania
  2. 2Surgical Oncology, ‘Prof. Dr. Ion Chiricuta’ Institute of Oncology, Cluj-Napoca, Romania
  3. 3Tumour Biology, ‘Prof. Dr. Ion Chiricuta’ Institute of Oncology, Cluj-Napoca, Romania
  4. 4Psychology, ‘Babes-Bolyai’ University, Cluj-Napoca, Romania
  5. 5Medical Oncology, ‘Prof. Dr. Ion Chiricuta’ Institute of Oncology, Cluj-Napoca, Romania
  6. 6Research, National Centre for Cell Science, Pune, India

Abstract

Introduction/Background Interleukin-6 (IL-6) has been implicated in various malignancies, including ovarian cancer. However, mixed results have been observed regarding IL-6 levels in different ovarian conditions. This meta-analysis was performed to determine IL-6 levels in the peritoneal fluid and peripheral blood among patients with various adnexal masses.

Methodology Most popular English databases were searched using a predefined search formula. All studies comparing IL-6 levels in plasma, serum or peritoneal fluid of patients with benign tumors, ovarian neoplasms, and healthy controls were included based on inclusion and exclusion criteria.

Results 5953 patients from 22 primary publications raging from 1994 to 2021 were included in the meta-analyses. A pooled IL-6 Mean Difference (MD) of 41 pg/mL for malignant tumors compared to benign ones, with a Confidence Interval (CI) between 19.8 and 62.2, a Z-score of 3.79, and statistical significance with a p=0.0002 was observed. Pooled results for healthy versus benign ovarian conditions showed an MD of 5.45 pg/mL for serum or plasma IL-6 measurements in favor of benign tumors (CI:.66 – 10.25, Z = 2.23 and p = 0.03). The analysis showed an MD for IL-6 levels of 19.59 pg/mL for healthy controls versus malignant ovarian tumors. Peritoneal fluid measurements regarding IL-6’s levels showed no significant difference between benign or malignant masses.

Abstract 2022-RA-437-ESGO Figure 1
Abstract 2022-RA-437-ESGO Figure 1

PRISMA flow diagram of included primary publications

Abstract 2022-RA-437-ESGO Figure 2
Abstract 2022-RA-437-ESGO Figure 2

Forrest plot included studies for the (A) serum healthy versus benign comparison of IL-6 levels; (B) serum healthy versus malignant comparison of IL-6 levels; © serum benign versus malignant ovarian conditions coparison of IL-6 levels; (D) ascites benign versus malignant ovarian conditions comparison of IL-6 levels

Conclusion Higher levels of plasma or serum IL-6 in ovarian neoplasia patients compared to benign conditions or healthy controls identify IL-6 as a discerning factor between benign or malignant ovarian tumors and a potential biomarker for ovarian malignancy.

https://doi.org/10.1136/ijgc-2022-ESGO.504

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.